Insider trading

Period: 120 months Stock: WHWK Minimum amount: $100K × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

32 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

32 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

32 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

32 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
32 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
32 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

32 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
16 Apr 2026
Giacobello Scott M. CHIEF FINANCIAL OFFICER
Sold at will
$584.81K 141,600 at 4.13
32.4%
Not planned
15 Apr 2026
Giacobello Scott M. CHIEF FINANCIAL OFFICER
Sold at will
$297.22K 77,000 at 3.86
15.0%
Not planned
14 Apr 2026
BALL BRYAN See remarks
Sold at will
$336.55K 92,460 at 3.64
18.9%
Not planned
9 Apr 2026
BALL BRYAN See remarks
Sold at will
$178.50K 50,000 at 3.57
8.7%
Not planned
8 Apr 2026
Lennon David James CHIEF EXECUTIVE OFFICER
Sold at will
$217.41K 63,945 at 3.40
10.7%
Not planned
7 Apr 2026
Lennon David James CHIEF EXECUTIVE OFFICER
Sold at will
$322.72K 94,087 at 3.43
13.6%
Not planned
6 Apr 2026
Lennon David James CHIEF EXECUTIVE OFFICER
Sold at will
$359.41K 102,395 at 3.51
12.9%
Not planned
2 Nov 2023
Desai Neil Executive Chairman · indirect
Sold at will
$141.10K 31,662 at 4.46
2.0%
Not planned
2 Oct 2023
Desai Neil Executive Chairman · indirect
Sold at will
$111.70K 25,569 at 4.37
1.5%
Not planned
5 Sep 2023
Desai Neil Executive Chairman · indirect
Sold at will
$118.32K 21,000 at 5.63
1.2%
Not planned
2 Aug 2023
Desai Neil Executive Chairman · indirect
Sold at will
$100.25K 19,290 at 5.20
1.1%
Not planned
1 Aug 2023
Desai Neil Executive Chairman · indirect
Sold at will
$118.52K 22,710 at 5.22
1.3%
Not planned
5 Jul 2023
Desai Neil Executive Chairman · indirect
Sold at will
$105.87K 16,171 at 6.55
0.9%
Not planned
5 Jun 2023
Desai Neil Executive Chairman · indirect
Sold at will
$140.42K 17,315 at 8.11
1.0%
Not planned
1 May 2023
Desai Neil Executive Chairman · indirect
Sold at will
$190.89K 24,479 at 7.80
1.3%
Not planned
26 Aug 2021
Dalal Anupam Director · indirect
Bought
$20.00M 1,529,402 at 13.08
opened
First buy on file
26 Aug 2021
Castelein Caley Director · indirect
Bought
$3.40M 259,998 at 13.08
opened
First buy on file
26 Apr 2019
Novartis Bioventures Ltd 10% owner · indirect
Sold, plan not stated
$142.87K 138,704 at 1.03
3.3%
25 Apr 2019
Novartis Bioventures Ltd 10% owner · indirect
Sold, plan not stated
$579.99K 563,096 at 1.03
11.9%
10 Apr 2019
Novartis Bioventures Ltd 10% owner · indirect
Sold, plan not stated
$152.85K 140,230 at 1.09
2.8%
1 Apr 2019
Novartis Bioventures Ltd 10% owner · indirect
Sold, plan not stated
$111.06K 116,909 at 0.95
2.2%
26 Mar 2019
Novartis Bioventures Ltd 10% owner · indirect
Sold, plan not stated
$179.54K 177,762 at 1.01
3.1%
28 Jun 2018
Satter Muneer A Director · indirect
Bought
$7.00M 1,818,182 at 3.85
55.8%
First buy on file
28 Jun 2018
Khuong Chau Quang Director · indirect
Bought
$2.99M 777,500 at 3.85
17.6%
First buy on file
28 Jun 2018
ORBIMED ADVISORS LLC Director · indirect
Bought
$2.99M 777,500 at 3.85
17.6%
First buy on file
15 Mar 2017
Satter Muneer A Director · indirect
Bought
$5.60M 1,120,000 at 5.00
52.8%
First buy on file
15 Mar 2017
ORBIMED ADVISORS LLC Director · indirect
Bought
$3.81M 762,995 at 5.00
20.9%
First buy on file
15 Mar 2017
Khuong Chau Quang Director · indirect
Bought
$3.81M 762,995 at 5.00
20.9%
First buy on file
15 Mar 2017
Novartis Bioventures Ltd 10% owner · indirect
Bought
$2.80M 560,000 at 5.00
10.7%
First buy on file
15 Mar 2017
Castelein Caley Director · indirect
Bought
$2.00M 400,000 at 5.00
33.0%
First buy on file
15 Mar 2017
WEISS PAUL M Director · indirect
Bought
$1.36M 272,302 at 5.00
20.9%
First buy on file
15 Mar 2017
Gardner Joseph H. See Remarks
Bought
$499.98K 99,996 at 5.00
20.3%
First buy on file
Showing 1–32 of 32.